Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash TriActiv

This article was originally published in The Gray Sheet

Executive Summary

Full European launch of the distal protection system is slated for May through a direct sales force as well as distributors. CE mark approval is announced Jan. 29. The balloon-protected flush extraction system is designed to prevent heart attacks during treatment for blocked saphenous vein grafts (SVGs) in previous coronary bypass patients. The device incorporates a distal protection balloon guidewire, flush catheter and debris extraction system. The firm is in the process of enrolling 800 patients at 50 centers in the U.S. trial...
Advertisement

Related Content

Kensey Nash Reviewing TriActiv Distal Protection Marketing Options
Advertisement
UsernamePublicRestriction

Register

MT016054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel